Cargando…

Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study

INTRODUCTION: Upper respiratory tract infections (URTI) are the most common illnesses affecting athletes, causing absences from training and competition. Salivary immunoglobulin A (sIgA) is the main immune factor in saliva, and a consistent association between low concentrations of sIgA and an incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertuccioli, Alexander, Gervasi, Marco, Annibalini, Giosuè, Binato, Beatrice, Perroni, Fabrizio, Rocchi, Marco B. L., Sisti, Davide, Amatori, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019894/
https://www.ncbi.nlm.nih.gov/pubmed/36936914
http://dx.doi.org/10.3389/fimmu.2023.1129060
_version_ 1784908131005890560
author Bertuccioli, Alexander
Gervasi, Marco
Annibalini, Giosuè
Binato, Beatrice
Perroni, Fabrizio
Rocchi, Marco B. L.
Sisti, Davide
Amatori, Stefano
author_facet Bertuccioli, Alexander
Gervasi, Marco
Annibalini, Giosuè
Binato, Beatrice
Perroni, Fabrizio
Rocchi, Marco B. L.
Sisti, Davide
Amatori, Stefano
author_sort Bertuccioli, Alexander
collection PubMed
description INTRODUCTION: Upper respiratory tract infections (URTI) are the most common illnesses affecting athletes, causing absences from training and competition. Salivary immunoglobulin A (sIgA) is the main immune factor in saliva, and a consistent association between low concentrations of sIgA and an increased incidence of URTIs has been reported. The oral probiotic Streptococcus salivarius K12 has been suggested to have the potential to improve oral diseases and mucosal barrier function. However, the effects of this probiotic on active young subjects performing a high-intensity training (HIT) program have not been investigated. METHODS: Active young students were randomised into a treated group (S. salivarius K12) and a control (placebo) group and asked to take the product daily for 30 days. After this period, participants performed a graded exercise test and five HIT sessions, all within 3 days. They were also asked to complete the Wisconsin Upper Respiratory Symptom Survey daily to monitor URTI’s presence. Before and after the 30 days, and at 0h, 24h and 72h after the last training session, saliva samples were collected to quantify sIgA level, secretion rate, and flow. The effect of S. salivarius K12 intake on these parameters was tested using an ANOVA for repeated measures. RESULTS: Twenty (M = 14, F = 6) young subjects (23.5 ± 2.3 years old) participated in the study. The total accumulated training load (sRPE) in the supplementation period was similar in the two groups (treated: 4345 ± 3441 AU; control: 4969 ± 4165 AU; p > 0.05). Considering both sIgA level and secretion rate, significant time (F((4,15)) = 3.38; p = 0.037; F((4,15)) = 6.00; p = 0.004) and time×group interactions (F((4,15)) = 2.49; p = 0.049; F((4,15)) = 5.01; p = 0.009) were reported, with the treated group showing higher sIgA levels at 72h post-exercise and increased secretion rate both at 0h and 72h. The number of URTI episodes was similar in the treated and control groups (χ² = 1.83; p > 0.05). CONCLUSION: This study demonstrates that relatively short-term S. salivarius K12 supplementation increased sIgA level and secretion in healthy subjects performing a demanding exercise-training programme composed of HIT sessions.
format Online
Article
Text
id pubmed-10019894
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100198942023-03-17 Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study Bertuccioli, Alexander Gervasi, Marco Annibalini, Giosuè Binato, Beatrice Perroni, Fabrizio Rocchi, Marco B. L. Sisti, Davide Amatori, Stefano Front Immunol Immunology INTRODUCTION: Upper respiratory tract infections (URTI) are the most common illnesses affecting athletes, causing absences from training and competition. Salivary immunoglobulin A (sIgA) is the main immune factor in saliva, and a consistent association between low concentrations of sIgA and an increased incidence of URTIs has been reported. The oral probiotic Streptococcus salivarius K12 has been suggested to have the potential to improve oral diseases and mucosal barrier function. However, the effects of this probiotic on active young subjects performing a high-intensity training (HIT) program have not been investigated. METHODS: Active young students were randomised into a treated group (S. salivarius K12) and a control (placebo) group and asked to take the product daily for 30 days. After this period, participants performed a graded exercise test and five HIT sessions, all within 3 days. They were also asked to complete the Wisconsin Upper Respiratory Symptom Survey daily to monitor URTI’s presence. Before and after the 30 days, and at 0h, 24h and 72h after the last training session, saliva samples were collected to quantify sIgA level, secretion rate, and flow. The effect of S. salivarius K12 intake on these parameters was tested using an ANOVA for repeated measures. RESULTS: Twenty (M = 14, F = 6) young subjects (23.5 ± 2.3 years old) participated in the study. The total accumulated training load (sRPE) in the supplementation period was similar in the two groups (treated: 4345 ± 3441 AU; control: 4969 ± 4165 AU; p > 0.05). Considering both sIgA level and secretion rate, significant time (F((4,15)) = 3.38; p = 0.037; F((4,15)) = 6.00; p = 0.004) and time×group interactions (F((4,15)) = 2.49; p = 0.049; F((4,15)) = 5.01; p = 0.009) were reported, with the treated group showing higher sIgA levels at 72h post-exercise and increased secretion rate both at 0h and 72h. The number of URTI episodes was similar in the treated and control groups (χ² = 1.83; p > 0.05). CONCLUSION: This study demonstrates that relatively short-term S. salivarius K12 supplementation increased sIgA level and secretion in healthy subjects performing a demanding exercise-training programme composed of HIT sessions. Frontiers Media S.A. 2023-03-02 /pmc/articles/PMC10019894/ /pubmed/36936914 http://dx.doi.org/10.3389/fimmu.2023.1129060 Text en Copyright © 2023 Bertuccioli, Gervasi, Annibalini, Binato, Perroni, Rocchi, Sisti and Amatori https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bertuccioli, Alexander
Gervasi, Marco
Annibalini, Giosuè
Binato, Beatrice
Perroni, Fabrizio
Rocchi, Marco B. L.
Sisti, Davide
Amatori, Stefano
Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study
title Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study
title_full Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study
title_fullStr Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study
title_full_unstemmed Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study
title_short Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study
title_sort use of streptococcus salivarius k12 in supporting the mucosal immune function of active young subjects: a randomised double-blind study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019894/
https://www.ncbi.nlm.nih.gov/pubmed/36936914
http://dx.doi.org/10.3389/fimmu.2023.1129060
work_keys_str_mv AT bertucciolialexander useofstreptococcussalivariusk12insupportingthemucosalimmunefunctionofactiveyoungsubjectsarandomiseddoubleblindstudy
AT gervasimarco useofstreptococcussalivariusk12insupportingthemucosalimmunefunctionofactiveyoungsubjectsarandomiseddoubleblindstudy
AT annibalinigiosue useofstreptococcussalivariusk12insupportingthemucosalimmunefunctionofactiveyoungsubjectsarandomiseddoubleblindstudy
AT binatobeatrice useofstreptococcussalivariusk12insupportingthemucosalimmunefunctionofactiveyoungsubjectsarandomiseddoubleblindstudy
AT perronifabrizio useofstreptococcussalivariusk12insupportingthemucosalimmunefunctionofactiveyoungsubjectsarandomiseddoubleblindstudy
AT rocchimarcobl useofstreptococcussalivariusk12insupportingthemucosalimmunefunctionofactiveyoungsubjectsarandomiseddoubleblindstudy
AT sistidavide useofstreptococcussalivariusk12insupportingthemucosalimmunefunctionofactiveyoungsubjectsarandomiseddoubleblindstudy
AT amatoristefano useofstreptococcussalivariusk12insupportingthemucosalimmunefunctionofactiveyoungsubjectsarandomiseddoubleblindstudy